Researchers improve vbectors for delivering hFVIII gene therapy to treat Hemophilia A

(Mary Ann Liebert, Inc./Genetic Engineering News) A new study examined 42 combinations of promoters and enhancers for human factor VIII (hFVIII) gene expression to identify the optimal adeno-associated virus (AAV)-based gene therapy delivery vector constructs to take forward into development.